A practical reference on peptide hormone: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
=== Processing issues and solutions === Nanocapsules tend to aggregate and become unstable. Thus, substances within capsules can leak. To control the instability, nanocapsules can be dried either through spray drying or freeze-drying (lyophilization). Spray drying – Solutions are sprayed into a drying medium. This method is more widely used in the food industry and used for encapsulation of many food products as flavors, minerals, colors, and vitamins. This method makes nanocapsules more stable, and increases shelf-life of foods. Freeze-drying – This process involves dehydration of materials that are heat-sensitive. Unlike spray drying, water is removed through the sublimation process without changing the structure or shape of the nanoparticles. Freeze-drying involves four states: freezing, primary drying, secondary drying, and storage. Because of the multiple stages involved, this method is considered to demand more energy and time.
Diabetes was diagnosed a few months ago The cat has no other serious disease Treatment includes insulin glargine administered twice daily The cat is monitored frequently during the first few months of treatment The cat eats a diet low in carbohydrates and high in protein. Cats may present with type 2 (insulin-resistant) diabetes, at least at first, but hyperglycemia and amyloidosis, left untreated, will damage the pancreas over time and progress to insulin-dependent diabetes. Glipizide and similar oral diabetic medicines designed for type 2 diabetic humans have been shown to increase amyloid production and amyloidosis and therefore may reduce likelihood of remission. Approximately one-third of cats who achieve remission will later relapse.
Further development yielded β-lactamase-resistant penicillins, including flucloxacillin, dicloxacillin, and methicillin. These were significant for their activity against β-lactamase-producing bacterial species, but were ineffective against the MRSA strains. Another development of the line of penicillins was the antipseudomonal penicillins, such as carbenicillin, ticarcillin, and piperacillin, useful for their activity against Gram-negative bacteria. The usefulness of the β-lactam ring was such that related antibiotics, including the mecillinams, the carbapenems and, most important, the cephalosporins, still retain it at the centre of their structures.
In 2007, US Fleet Tracking provided live GPS tracking to Gameday Management Group for use at the Super Bowl, tracking AFC and NFC Team buses, media buses, press buses, halftime entertainers, team owners and team family limousines, and other critical assets. US Fleet Tracking continues to provide these services for the Super Bowl each year, as it has each year since 2007 (through 2020). In 2013, US Fleet Tracking sponsored the FLS Microjet for its appearance at the EAA AirVenture Oshkosh airshow in Oshkosh, Wisconsin. The company demonstrated its live tracking technology at the event by installing its proprietary GPS equipment on the FLS Microjet and allowing the public to follow the course of the aircraft via a website in real time during the exhibition.
Sources: en.wikipedia.org
Upon Allied victory concluding the Second World War (1939–1945), the members of the Grand Alliance resumed their pre-war geopolitical rivalries and ideological tensions which disunity broke their anti-fascist wartime alliance through the concept of totalitarianism into the anti-communist Western Bloc and the Marxist–Leninist Eastern Bloc. The renewed competition for geopolitical hegemony resulted in the bi-polar Cold War (1947–1991), a protracted state of tension (military and diplomatic) between the United States and the Soviet Union which often threatened a Soviet–American nuclear war, but it usually featured proxy wars in the Third World. With the end of the Grand Alliance and the start of the Cold War, anti-fascism became part of both the official ideology and language of communist states, especially in East Germany. Fascist and anti-fascism, with the latter used to mean a general anti-capitalist struggle against the Western world and NATO, became epithets widely used by Marxist–Leninists to smear their opponents, including democratic socialists, libertarian socialists, social democrats and other anti-Stalinist leftists. The events that precipitated the Cold War in Europe were the Soviet and Yugoslav, Bulgarian and Albanian military interventions to the Greek Civil War (1944–1949) on behalf of the Communist Party of Greece; and the Berlin Blockade (1948–1949) by the Soviet Union.
== External links == Nerve+Growth+Factor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: P01138 (Human Beta-nerve growth factor) at the PDBe-KB. Overview of all the structural information available in the PDB for UniProt: P01139 (Mouse Beta-nerve growth factor) at the PDBe-KB.
=== Ustekinumab === Ustekinumab was approved by the FDA in 2009 for the treatment of plaque psoriasis, making it the first and so far the only approved interleukin antagonist. It is also used for the treatment of Crohn's disease and psoriatic arthritis. Studies suggest that the blocking of IL-23, rather than IL-12, has the greatest effect on the therapeutic benefits of ustekinumab.
=== Sigma bond cleavage === The ionization of alkanes weakens the C-C bond, ultimately resulting in the decomposition. As the bond breaks, a charged, even electron species (R+) and a neutral radical species (R•) are generated. Highly substituted carbocations are more stable than the nonsubstituted ones. An example is depicted below.
== Toxicity and overdose == The toxicity of nutmeg constituents such as myristicin has been studied and described in animals and in humans. There is at least one known case of death in humans, an eight-year-old boy who ate two whole nutmegs, became comatose, and then died within 24 hours, published in 1908. Other fatal cases have also since been reported. Cats are more sensitive to the toxic effects of nutmeg or isolated myristicin and after a delay of a few days die due to severe hepatotoxicity when given these substances in sufficient amounts. Hepatoxicity has also been observed in guinea pigs and rabbits given very high doses of nutmeg.
Sources: en.wikipedia.org
=== Neutrinos === The study of beta decay provided the first physical evidence for the existence of the neutrino. In both alpha and gamma decay, the resulting alpha or gamma particle has a narrow energy distribution, since the particle carries the energy from the difference between the initial and final nuclear states. However, the kinetic energy distribution, or spectrum, of beta particles measured by Lise Meitner and Otto Hahn in 1911 and by Jean Danysz in 1913 showed multiple lines on a diffuse background. These measurements offered the first hint that beta particles have a continuous spectrum. In 1914, James Chadwick used a magnetic spectrometer with one of Hans Geiger's new counters to make more accurate measurements which showed that the spectrum was continuous. The results, which appeared to be in contradiction to the law of conservation of energy, were validated by means of calorimetric measurements in 1929 by Lise Meitner and Wilhelm Orthmann. If beta decay were simply electron emission as assumed at the time, then the energy of the emitted electron should have a particular, well-defined value. For beta decay, however, the observed electrons had a broad distribution of energies. A second problem is related to the conservation of angular momentum. Molecular band spectra showed that the nuclear spin of nitrogen-14 is 1 (i.e., equal to the reduced Planck constant) and more generally that the spin is integral for nuclei of even mass number and half-integral for nuclei of odd mass number. This was later explained by the proton-neutron model of the nucleus.
== Development == Mast cells are considered to have originated nearly 500 million years ago, in urochordates, making them one of the most ancient types of immune cells. Mast cells (MCs) are specialized immune cells derived through hematopoiesis, the formation of blood cell components. Mast cells develop from circulating mast cell progenitors (MCps). Once they are recruited to a given type of connective or mucosal tissue, they specialize and become resident mast cells. Mature MCs exhibit context-specific effector properties related to tissue types and diseases, and are highly varied. Mast cells in different tissues, such as gut and skin, will exhibit different physical, behavioral, and biochemical characteristics and functions. Mast cells may have dual methods of origin in the hematopoietic system. In 1989, Leonore Herzenberg and Leonard Herzenberg proposed that different types of stem cells produce specific types of immune cells through multiple waves of development. Specific types of immune cells have been shown to arise sequentially at different points in embryonic development. The original layered immune theory proposed that hematopoietic stem cells (HSCs) were the basis for such development. In the classical sequence of hematopoiesis, hematopoietic stem cells (HSCs) were described as becoming multipotent progenitors (MPPs), then differentiating into common myeloid progenitors (CMPs), followed by granulocyte/monocyte progenitors (GMPs). GMPs then differentiated into mast cells and basophils. However, lineage relationships in human hematopoiesis have been hotly debated.
== External links == Food for Thought: Mushrooming Concerns "Science News Online" article on T. flavovirens (T. equestre). Tricholoma equestre poisoning "About Health Canada" article on Tricholoma equestre poisoning. Recent Poisonings from Edible Mushrooms! A report on a few new kinds of mushroom poisoning. Riddarmusseronen kan vara giftig Swedish article on T. flavovirens and its toxicity. Matportalen: Matsoppen som ble giftsopp Norwegian article on T. equestre.
=== Announcement === Prompted by the government, the Rhodesian Broadcasting Corporation told the public to stand by for an important announcement from the Prime Minister at 13:15 local time. Smith went first to Government House to inform Gibbs that his Cabinet had declared independence, then to Pockets Hill Studios in east Salisbury to announce UDI to the nation. He read the proclamation aloud, then stated that independence had been declared because it had become "abundantly clear that it is the policy of the British government to play us along with no real intention of arriving at a solution which we could possibly accept ... I promised the people of this country that I would continue to negotiate to the bitter end and that I would leave no stone unturned in my endeavours to secure an honourable and mutually accepted settlement; it now falls to me to tell you that negotiations have come to an end". Smith said that he believed that he would be remiss in his duty if he allowed Rhodesia to continue to "drift in its present paralysing state of uncertainty", and that following Britain's abandonment of the Federation his government was determined that "the same will never be allowed to happen here". He claimed that UDI did not mark "a diminution in the opportunities which our African people have to advance and prosper in Rhodesia", described "racial harmony in Africa" as part of his agenda and condemned black Rhodesian activities as attempts to "blackmail the British government into ... handing the country over to irresponsible rule".
== Honors and awards == Bumpus has received numerous recognitions from the United States government for her work. In 2016, President Obama awarded her a Presidential Early Career Award for Scientists and Engineers, "the highest honor bestowed by the United States Government on science and engineering professionals in the early stages of their independent research careers". She delivered the National Institute of General Medical Sciences (NIGMS) Director's Early-Career Investigator Lecture in 2017, and was the Congressional Biomedical Research Caucus's invited speaker in March 2018, lecturing about informing consumers about drug metabolism. Bumpus became a fellow of the American Association for the Advancement of Science, in its Section on Pharmaceutical Sciences, in 2021. In 2022, she was elected to the National Academy of Medicine. Additional awards she has received include:
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.